SCGN

Overview

SCGN (Secretagogin) is a calcium-binding protein validated as an IHC protein marker for the MG2 molecular group of meningiomas in an integrative molecular classification.

Alterations observed in the corpus

  • SCGN protein expression was validated by IHC as a discriminative marker for the MG2 (NF2-wildtype, TRAF7/AKT1/KLF4/SMO-driven) molecular group of meningiomas; the four-marker IHC panel (S100B, SCGN, ACADL, MCM2) was proposed to enable molecular group assignment in conventional neuropathology laboratories PMID:34433969.

Cancer types (linked)

  • MNG — IHC marker for MG2 molecular group in the integrative meningioma classification PMID:34433969.

Co-occurrence and mutual exclusivity

Therapeutic relevance

  • MG2 tumors (benign NF2-wildtype) may be amenable to targeted therapies directed at TRAF7/AKT1/KLF4/SMO pathways; SCGN IHC could facilitate patient selection PMID:34433969.

Open questions

  • Independent validation of the IHC panel in external meningioma cohorts is required PMID:34433969.

Sources

This page was processed by crosslinker on 2026-04-11.